BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 5, 2026
Home » Authors » Mark McCarty

Articles by Mark McCarty

Washington roundup: Lurie tapped as acting associate policy, planning commissioner

Sep. 20, 2012
By Mark McCarty

Washington roundup: MHRA wants more frequent follow-up of St. Jude's Riatas

Sep. 19, 2012
By Mark McCarty

Washington roundup: AAMI, UL eye standards for device interoperability

Sep. 18, 2012
By Mark McCarty

Washington roundup: OMB: Sequester would reduce FDA budget by nearly $320M

Sep. 17, 2012
By Mark McCarty

Chickens or lemmings? Washington and the FDA budget

Sep. 16, 2012
By Mark McCarty
There’s a lot of consternation and maybe even a little constipation of late about the U.S. federal budget, and rightly so. If the White House and Congress can’t come to some resolution about budget sequestration, the FDA budget could tighten enough that user fees would disappear, which would cripple the agency. Complicating matters further is the series of tax issues – a convergence dubbed the fiscal cliff – that ripen at the end of this year, giving everyone inside the Beltway more to worry about. This is all difficult enough without an election, so it’s easy to be pessimistic. And...
Read More

Washington roundup: Sequestration may not affect device user fee sums in 2013

Sep. 14, 2012
By Mark McCarty

Jim Mazzo: A case of loose lips or a deliberate slip?

Sep. 13, 2012
By Mark McCarty
There isn’t much that stays behind closed doors these days, and the case of Jim Mazzo, the outgoing CEO of Advanced Medical Optics, might be nothing more than a case of camaraderie-loosened lips … or something more toxic. To recap, Mazzo, has been charged by the SEC with insider trading violations thanks to trades made by several former professional baseball players. The thread of the story seems to be that Mazzo told Doug DeCinces in 2008 of the then-impending move by Abbott to acquire AMO. It appears DeCinces then relayed the scoop to a couple of other former major league...
Read More

Washington roundup: Hefty warning letter to GMD delivers coup de grace to firm

Sep. 13, 2012
By Mark McCarty

Washington roundup: DME bidding process under attack again on Capitol Hill

Sep. 12, 2012
By Mark McCarty

Washington roundup: FTC advises makers of mobile medical apps about false claims

Sep. 11, 2012
By Mark McCarty
Previous 1 2 … 422 423 424 425 426 427 428 429 430 … 579 580 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 5, 2025.
  • Today's news in brief

    Briefs
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Art concept for medical research

    MicroRNAs in circulating extracellular vesicles as IPF biomarkers

    BioWorld Science
    MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
  • Brain illustration

    MJFF grant supports Bexorg’s translational biomarker work

    BioWorld Science
    Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
  • Brain and DNA

    REST emerges as biomarker in ALS, knockdown improves ALS symptoms

    BioWorld Science
    About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing